Adalimumab/certolizumab pegol/etanerceptVarious infections: 5 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1740卷 / 1期

关键词：

D O I：

10.1007/s40278-019-57909-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：16 / 16

相关论文

共 50 条

[41] Certolizumab pegol/leflunomidePyomyositis: case report
Reactions Weekly, 2018, 1720 (1) : 73 - 73
[42] Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Alistair I Henry
Haiping Gong
Andrew M Nesbitt
Journal of Translational Medicine, 9 (Suppl 2)
[43] Comparison of the penetration of certolizumab pegol and adalimumab in inflamed and noninflamed mouse tissue
Nesbitt, Andrew M.
Palframan, Roger T.
Vugler, Alex D.
Moore, Adrian R.
Baker, Mark B.
Foulkes, Roland
Gozzard, Neil
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S472 - S472
[44] EtanerceptVarious toxicities: 15 case reports
Reactions Weekly, 2025, 2043 (1) : 162 - 162
[45] EtanerceptVarious toxicities: 2 case reports
Reactions Weekly, 2017, 1669 (1) : 125 - 125
[46] EtanerceptVarious toxicities: 4 case reports
Reactions Weekly, 2023, 1968 (1) : 140 - 140
[47] Certolizumab pegol/etanercept/tocilizumabNeutrophilic dermatosis, leukocytoclastic vasculitis and psoriasis: 3 case reports
Reactions Weekly, 2018, 1721 (1) : 76 - 76
[48] EtanerceptVarious toxicities: 3 case reports
Reactions Weekly, 2015, 1564 (1) : 82 - 82
[49] Adalimumab/etanerceptNeutropenia: 5 case reports
Reactions Weekly, 2010, 1311 (1) : 7 - 7
[50] Adalimumab/infliximabHistoplasmosis: 5 case reports
Reactions Weekly, 2011, 1336 (1) : 5 - 5

← 1 2 3 4 5 →